STK11 and non-small cell lung carcinoma: To create a data set that could be used to validate our human NSCLC cachexia screen, we procured a list of 246 patients with NSCLC who had blood collected for evaluation of variants in 74 genes (including STK11/LKB1) with the Guardant360 Companion Diagnostic (CDx) circulating tumor DNA (ctDNA) assay as part of an IRB-approved protocol (Figure 6A).